We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche's NDA for SMA Drug Gets Expanded Review From FDA
Read MoreHide Full Article
Roche Holding AG (RHHBY - Free Report) announced that the FDA has extended the review period of its new drug application (NDA) for its investigational agent risdiplam, currently being developed for the treatment of patients with spinal muscular atrophy (SMA). A decision from the regulatory body is now awaited on Aug 24, 2020, which was previously expected on May 24, 2020.
The FDA’s decision to extend its review timeline by three months was based on the recent submission of additional data by Roche including data from part 2 of the pivotal SUNFISH study on risdiplam.
Notably, in November 2019, the FDA accepted the NDA for risdiplam for the treatment of SMA.
The NDA was based on 12-month data from the pivotal FIREFISH and SUNFISH studies, which evaluated risdiplam across a broad patient population suffering type 1, 2 or 3 SMA.
In February 2020, Roche announced one-year data from the part 2 of SUNFISH study evaluating risdiplam in people aged from two to 25 years with type 2 or 3 SMA. The study showed that change from baseline in the primary endpoint of the Motor Function Measure scale (MFM-32) was significantly greater in patients treated with risdiplam compared to placebo.
The additional data submitted by Roche could help a broad range of patients afflicted with SMA to gain access to risdiplam upon potential approval. Given the volume of this additional data, the FDA requires more time for review.
The company plans to submit a marketing authorization application for risdiplam to the European Medicines Agency in mid-2020.
Shares of Roche have lost 1.5% so far this year compared with the industry’s decline of 7.8%.
We remind investors that Roche leads the clinical development of risdiplam as part of its collaboration with the SMA Foundation and PTC Therapeutics (PTCT - Free Report) .
Risdiplam is an investigational, orally administered liquid survival motor neuron-2 (SMN-2) splicing modifier for SMA. The drug is being evaluated in a broad clinical trial program comprising from newborn babies to 60-year olds with SMA.
We note that successful development of risdiplam will diversify Roche’s portfolio. However, competition is stiff in the SMA market from the likes of Biogen’s (BIIB - Free Report) Spinraza and Novartis’ (NVS - Free Report) gene therapy, Zolgensma.
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Image: Bigstock
Roche's NDA for SMA Drug Gets Expanded Review From FDA
The FDA’s decision to extend its review timeline by three months was based on the recent submission of additional data by Roche including data from part 2 of the pivotal SUNFISH study on risdiplam.
Notably, in November 2019, the FDA accepted the NDA for risdiplam for the treatment of SMA.
The NDA was based on 12-month data from the pivotal FIREFISH and SUNFISH studies, which evaluated risdiplam across a broad patient population suffering type 1, 2 or 3 SMA.
In February 2020, Roche announced one-year data from the part 2 of SUNFISH study evaluating risdiplam in people aged from two to 25 years with type 2 or 3 SMA. The study showed that change from baseline in the primary endpoint of the Motor Function Measure scale (MFM-32) was significantly greater in patients treated with risdiplam compared to placebo.
The additional data submitted by Roche could help a broad range of patients afflicted with SMA to gain access to risdiplam upon potential approval. Given the volume of this additional data, the FDA requires more time for review.
The company plans to submit a marketing authorization application for risdiplam to the European Medicines Agency in mid-2020.
Shares of Roche have lost 1.5% so far this year compared with the industry’s decline of 7.8%.
We remind investors that Roche leads the clinical development of risdiplam as part of its collaboration with the SMA Foundation and PTC Therapeutics (PTCT - Free Report) .
Risdiplam is an investigational, orally administered liquid survival motor neuron-2 (SMN-2) splicing modifier for SMA. The drug is being evaluated in a broad clinical trial program comprising from newborn babies to 60-year olds with SMA.
We note that successful development of risdiplam will diversify Roche’s portfolio. However, competition is stiff in the SMA market from the likes of Biogen’s (BIIB - Free Report) Spinraza and Novartis’ (NVS - Free Report) gene therapy, Zolgensma.
Zacks Rank
Roche currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
See 5 Stocks Set to Double>>